The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Eskaflam     N-(4-nitro-2-phenoxy- phenyl)methanesulfona...

Synonyms: Orthobid, Redaflam, Sulidene, Aldoron, Mesulid, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Flogovital


Psychiatry related information on Flogovital


High impact information on Flogovital


Chemical compound and disease context of Flogovital


Biological context of Flogovital


Anatomical context of Flogovital


Associations of Flogovital with other chemical compounds

  • By contrast, nimesulide had no effect on both A beta peptides and NF-kappa B. Consistently, mice receiving indomethacin, but no nimesulide, showed a significant reduction in the amyloid burden compared with placebo [26].
  • These NSAIDs markedly reduced the levels of the cellular APP holoprotein, further accelerating non-amyloidogenic processes. sAPP alpha release, induced by nimesulide and Thal, was modulated by inhibitors of protein kinase C and Erk mitogen-activated protein (MAP) kinase [27].
  • Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen [22].
  • Production of prostaglandin E(2) and prostacyclin by gastric biopsies, also COX-1 dependent, was inhibited by naproxen, but not by nimesulide [22].
  • METHODS: Twenty-one patients undergoing PTCA while receiving aspirin 300 mg daily or aspirin plus the selective COX-2 inhibitor nimesulide were compared with 13 patients treated only with fradafiban, a glycoprotein IIb/IIIa antagonist [28].

Gene context of Flogovital

  • In COX-2-positive pancreatic cancer, the nimesulide-induced increase of VEGF production by the cancer cells was offset by a decrease in VEGF production by the nonmalignant cell types leading to reduced tumor angiogenesis and growth [12].
  • Nimesulide-induced hepatic mitochondrial injury in heterozygous Sod2(+/-) mice [25].
  • Our previous study demonstrated that COX-2 selective inhibitor nimesulide decreased aromatase activity from the transcriptional level in breast cancer cells [29].
  • Conversely, chronic treatment of the hCOX-2 transgenics with the preferential COX-2 inhibitor nimesulide reversed the hCOX-2-mediated decrease of cortical p18(INK4) mRNA expression in the brain [30].
  • Molecular models of the complex between the selective COX-2 inhibitor nimesulide and the cyclooxygenase active site of human prostaglandin-endoperoxide synthase-2 have been built using a combination of homology modelling, conformational searching and automated docking techniques [31].

Analytical, diagnostic and therapeutic context of Flogovital


  1. Nimesulide and neonatal renal failure. Balasubramaniam, J. Lancet (2000) [Pubmed]
  2. Neonatal end-stage renal failure associated with maternal ingestion of cyclo-oxygenase-type-1 selective inhibitor nimesulide as tocolytic. Peruzzi, L., Gianoglio, B., Porcellini, M.G., Coppo, R. Lancet (1999) [Pubmed]
  3. Nimesulide, thrombocytopenic purpura, and human immunodeficiency virus (HIV) infection. Pasticci, M.B., Menichetti, F., Di Candilo, F. Ann. Intern. Med. (1990) [Pubmed]
  4. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Praticò, D., Tillmann, C., Zhang, Z.B., Li, H., FitzGerald, G.A. Proc. Natl. Acad. Sci. U.S.A. (2001) [Pubmed]
  5. Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. Shariat-Madar, Z., Mahdi, F., Warnock, M., Homeister, J.W., Srikanth, S., Krijanovski, Y., Murphey, L.J., Jaffa, A.A., Schmaier, A.H. Blood (2006) [Pubmed]
  6. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Aisen, P.S., Schmeidler, J., Pasinetti, G.M. Neurology (2002) [Pubmed]
  7. Nimesulide-induced acute hepatitis: evidence from six cases. Van Steenbergen, W., Peeters, P., De Bondt, J., Staessen, D., Büscher, H., Laporta, T., Roskams, T., Desmet, V. J. Hepatol. (1998) [Pubmed]
  8. Risk factors of adverse drug reaction caused by nimesulide in Shanghai patients with osteoarthropathy. Shi, W., Wang, Y.M., Li, S.L., Yan, M., Chen, B.Y., Chen, N.N., Li, D. Drugs under experimental and clinical research. (2003) [Pubmed]
  9. Comparative efficacy and tolerability of nimesulide and piroxicam in osteoarthritis with specific reference to chondroprotection: a double blind randomised study. Roy, V., Gupta, U., Sharma, S., Dhaon, B.K., Singh, N.P., Gulati, P. Journal of the Indian Medical Association. (1999) [Pubmed]
  10. Protective effect of cyclooxygenase-2 (COX-2) inhibitors but not non-selective cyclooxygenase (COX)-inhibitors on ethanol withdrawal-induced behavioural changes. Dhir, A., Naidu, P.S., Kulkarni, S.K. Addiction biology. (2005) [Pubmed]
  11. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Hiraga, T., Myoui, A., Choi, M.E., Yoshikawa, H., Yoneda, T. Cancer Res. (2006) [Pubmed]
  12. Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. Eibl, G., Takata, Y., Boros, L.G., Liu, J., Okada, Y., Reber, H.A., Hines, O.J. Cancer Res. (2005) [Pubmed]
  13. The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Fantappiè, O., Masini, E., Sardi, I., Raimondi, L., Bani, D., Solazzo, M., Vannacci, A., Mazzanti, R. Hepatology (2002) [Pubmed]
  14. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Shiotani, H., Denda, A., Yamamoto, K., Kitayama, W., Endoh, T., Sasaki, Y., Tsutsumi, N., Sugimura, M., Konishi, Y. Cancer Res. (2001) [Pubmed]
  15. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Okajima, E., Denda, A., Ozono, S., Takahama, M., Akai, H., Sasaki, Y., Kitayama, W., Wakabayashi, K., Konishi, Y. Cancer Res. (1998) [Pubmed]
  16. Assessment of the efficacy and safety of nimesulide vs naproxen in paediatric patients with respiratory tract infections. A comparative single-blind study. Salmòn Rodriguez, L.E., Arista Viveros, H.A., Lujan, M.E., Maciel, R.M., Trujillo, C.L., Lopez, E. Drugs (1993) [Pubmed]
  17. A comparison of nimesulide and diclofenac in the treatment of acute superficial thrombophlebitis. Ferrari, E., Pratesi, C., Scaricabarozzi, I. Drugs (1993) [Pubmed]
  18. A comparison of nimesulide vs paracetamol in the treatment of pyrexia in the elderly. Cunietti, E., Monti, M., Viganò, A., D'Aprile, E., Saligari, A., Scafuro, E., Scaricabarozzi, I. Drugs (1993) [Pubmed]
  19. Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism. Kalajdzic, T., Faour, W.H., He, Q.W., Fahmi, H., Martel-Pelletier, J., Pelletier, J.P., Di Battista, J.A. Arthritis Rheum. (2002) [Pubmed]
  20. Enhancement of phosphorylation and transcriptional activity of the glucocorticoid receptor in human synovial fibroblasts by nimesulide, a preferential cyclooxygenase 2 inhibitor. Di Battista, J.A., Zhang, M., Martel-Pelletier, J., Fernandes, J., Alaaeddine, N., Pelletier, J.P. Arthritis Rheum. (1999) [Pubmed]
  21. A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. Rowlinson, S.W., Kiefer, J.R., Prusakiewicz, J.J., Pawlitz, J.L., Kozak, K.R., Kalgutkar, A.S., Stallings, W.C., Kurumbail, R.G., Marnett, L.J. J. Biol. Chem. (2003) [Pubmed]
  22. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Shah, A.A., Thjodleifsson, B., Murray, F.E., Kay, E., Barry, M., Sigthorsson, G., Gudjonsson, H., Oddsson, E., Price, A.B., Fitzgerald, D.J., Bjarnason, I. Gut (2001) [Pubmed]
  23. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Totzke, G., Schulze-Osthoff, K., Jänicke, R.U. Oncogene (2003) [Pubmed]
  24. Establishment and characterization of a human lung cancer cell line NCI-H460-LNM35 with consistent lymphogenous metastasis via both subcutaneous and orthotopic propagation. Kozaki, K., Miyaishi, O., Tsukamoto, T., Tatematsu, Y., Hida, T., Takahashi, T., Takahashi, T. Cancer Res. (2000) [Pubmed]
  25. Nimesulide-induced hepatic mitochondrial injury in heterozygous Sod2(+/-) mice. Ong, M.M., Wang, A.S., Leow, K.Y., Khoo, Y.M., Boelsterli, U.A. Free Radic. Biol. Med. (2006) [Pubmed]
  26. Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Sung, S., Yang, H., Uryu, K., Lee, E.B., Zhao, L., Shineman, D., Trojanowski, J.Q., Lee, V.M., Praticò, D. Am. J. Pathol. (2004) [Pubmed]
  27. Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein. Avramovich, Y., Amit, T., Youdim, M.B. J. Biol. Chem. (2002) [Pubmed]
  28. Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor. Kearney, D., Byrne, A., Crean, P., Cox, D., Fitzgerald, D.J. J. Am. Coll. Cardiol. (2004) [Pubmed]
  29. Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells. Su, B., Landini, S., Davis, D.D., Brueggemeier, R.W. J. Med. Chem. (2007) [Pubmed]
  30. Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity. Mirjany, M., Ho, L., Pasinetti, G.M. J. Pharmacol. Exp. Ther. (2002) [Pubmed]
  31. Automated docking and molecular dynamics simulations of nimesulide in the cyclooxygenase active site of human prostaglandin-endoperoxide synthase-2 (COX-2). García-Nieto, R., Pérez, C., Gago, F. J. Comput. Aided Mol. Des. (2000) [Pubmed]
  32. the selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model. Nam, K.T., Hahm, K.B., Oh, S.Y., Yeo, M., Han, S.U., Ahn, B., Kim, Y.B., Kang, J.S., Jang, D.D., Yang, K.H., Kim, D.Y. Clin. Cancer Res. (2004) [Pubmed]
  33. Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator- activated receptor-gamma. Shaik, M.S., Chatterjee, A., Singh, M. Clin. Cancer Res. (2004) [Pubmed]
  34. The pharmacokinetic profile of nimesulide in healthy volunteers. Bernareggi, A. Drugs (1993) [Pubmed]
  35. Double-blind study of nimesulide in divers with inflammatory disorders of the ear, nose and throat. Banchini, G., Scaricabarozzi, I., Montecorboli, U., Ceccarelli, A., Chiesa, F., Ditri, L., Mazzer, G., Moroni, R., Viola, M., Roggia, F. Drugs (1993) [Pubmed]
  36. Inhibition of PGE2 production by nimesulide compared with diclofenac in the acutely inflamed joint of patients with arthritis. Duffy, T., Belton, O., Bresnihan, B., FitzGerald, O., FitzGerald, D. Drugs (2003) [Pubmed]
WikiGenes - Universities